Mutations within the kinase domain of BCR::ABL1 are the most extensively studied mechanisms of TKI resistance in CML; however, these mutations fail to explain 20–40% of resistant cases [4]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.